IN2012DN09335A - - Google Patents

Download PDF

Info

Publication number
IN2012DN09335A
IN2012DN09335A IN9335DEN2012A IN2012DN09335A IN 2012DN09335 A IN2012DN09335 A IN 2012DN09335A IN 9335DEN2012 A IN9335DEN2012 A IN 9335DEN2012A IN 2012DN09335 A IN2012DN09335 A IN 2012DN09335A
Authority
IN
India
Prior art keywords
compositions
methods
synthetic retinal
retinal derivatives
retinoid
Prior art date
Application number
Other languages
English (en)
Inventor
Krzysztof Palczewski
Mathew Batten
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IN2012DN09335A publication Critical patent/IN2012DN09335A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN9335DEN2012 2004-06-18 2005-06-20 IN2012DN09335A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (1)

Publication Number Publication Date
IN2012DN09335A true IN2012DN09335A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=35782277

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9335DEN2012 IN2012DN09335A (enrdf_load_stackoverflow) 2004-06-18 2005-06-20

Country Status (26)

Country Link
US (8) US7951841B2 (enrdf_load_stackoverflow)
EP (5) EP1765322B1 (enrdf_load_stackoverflow)
JP (2) JP5166026B2 (enrdf_load_stackoverflow)
KR (4) KR20140140616A (enrdf_load_stackoverflow)
CN (2) CN1988898B (enrdf_load_stackoverflow)
AU (1) AU2005257997B2 (enrdf_load_stackoverflow)
BR (1) BRPI0511396B1 (enrdf_load_stackoverflow)
CA (2) CA2571049C (enrdf_load_stackoverflow)
CY (2) CY1114873T1 (enrdf_load_stackoverflow)
DK (2) DK2397133T3 (enrdf_load_stackoverflow)
ES (4) ES2644981T3 (enrdf_load_stackoverflow)
HR (1) HRP20140116T1 (enrdf_load_stackoverflow)
HU (1) HUE036596T2 (enrdf_load_stackoverflow)
IL (4) IL180078A (enrdf_load_stackoverflow)
IN (1) IN2012DN09335A (enrdf_load_stackoverflow)
LT (1) LT2397133T (enrdf_load_stackoverflow)
MX (2) MXPA06014750A (enrdf_load_stackoverflow)
NO (1) NO339969B1 (enrdf_load_stackoverflow)
NZ (2) NZ587006A (enrdf_load_stackoverflow)
PL (2) PL1765322T3 (enrdf_load_stackoverflow)
PT (2) PT1765322E (enrdf_load_stackoverflow)
RS (1) RS53178B (enrdf_load_stackoverflow)
RU (2) RU2554003C2 (enrdf_load_stackoverflow)
SI (2) SI1765322T1 (enrdf_load_stackoverflow)
WO (1) WO2006002097A2 (enrdf_load_stackoverflow)
ZA (1) ZA200700368B (enrdf_load_stackoverflow)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
CN1988898B (zh) 2004-06-18 2012-12-26 华盛顿大学 用于治疗视觉障碍的视黄醛衍生物及其使用方法
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
AU2005314039B2 (en) * 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
CA2657015A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
EP2069391A4 (en) * 2006-07-27 2009-12-30 Univ Florida COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES
US8338394B2 (en) * 2006-10-12 2012-12-25 Case Western Reserve University Methods for treating metabolic diseases
BRPI0810063A2 (pt) * 2007-04-20 2014-10-14 Acucela Inc Composto, composição farmacêutica, e, métodos para modular fluxo de cromóforo em um ciclo retinóide, para tratar uma doença ou distúrbio oftálmico em um indivíduo, para inibir adaptação ao escuro em uma célula fotorreceptora de bastão da retina, para inibir regeneração de rodopsina em uma célula fotoreceptora de bastão da retina, para reduzir isquemia em um olho de um indivíduo, para inibir neovascularização na retina de um olho de um indivíduo, e para inibir degeneração de uma célula da retina em uma retina
BRPI0908154A2 (pt) 2008-02-11 2015-08-11 Univ Washington Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009133552A2 (en) * 2008-04-29 2009-11-05 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
IN2012DN00352A (enrdf_load_stackoverflow) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
MX2012003220A (es) * 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
JP6250389B2 (ja) * 2010-04-19 2017-12-20 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
CA2816968C (en) * 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
US10226536B2 (en) * 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
AU2013232697B2 (en) * 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
CA2875798A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
WO2013188727A2 (en) * 2012-06-15 2013-12-19 The Children's Hospital Of Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
KR20190020661A (ko) * 2016-04-28 2019-03-04 스파크 테라퓨틱스, 인코포레이티드 아이소메로하이드롤라아제를 인코딩하는 바이러스 벡터에 대한 상대 효능 검정
EP4472736A1 (en) * 2022-02-04 2024-12-11 New York University Use of retinoids for treatment of atrial fibrillation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) * 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンa類可溶化点眼剤
JPH09511507A (ja) 1994-04-04 1997-11-18 フリーマン,ウイリアム・アール 上昇した眼圧を治療するためのホスホニルメトキシアルキルヌクレオシドの使用
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
EA199700289A1 (ru) * 1995-04-03 1998-04-30 Джонсон энд Джонсон Конзьюмер Продактс, Инк. Композиции для ухода за кожей, содержащие ретиноиды и липосомы
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
CA2373237A1 (en) 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
US6878747B2 (en) 2001-01-26 2005-04-12 Steven A. Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) * 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CN1741811A (zh) 2002-03-29 2006-03-01 马克西姆医药公司 Rom产生与释放抑制剂治疗和预防眼内损伤的用途
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
AU2005215778B2 (en) 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン, 視覚サイクルの阻害による網膜症の予防
CN1988898B (zh) 2004-06-18 2012-12-26 华盛顿大学 用于治疗视觉障碍的视黄醛衍生物及其使用方法
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
JP2008515778A (ja) 2004-08-18 2008-05-15 シリオン セラピューティクス, インコーポレイテッド 眼の状態を13−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
ES2449150T3 (es) 2007-09-12 2014-03-18 The Trustees Of Columbia University In The City Of New York Compuestos y métodos para tratar la degeneración muscular
BRPI0908154A2 (pt) 2008-02-11 2015-08-11 Univ Washington Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade

Also Published As

Publication number Publication date
DK1765322T3 (da) 2014-02-10
BRPI0511396A (pt) 2007-12-04
KR101490145B1 (ko) 2015-02-05
US20130072556A1 (en) 2013-03-21
EP2397130A3 (en) 2012-10-31
IL230241A (en) 2015-06-30
CN102976937B (zh) 2016-12-21
EP1765322B1 (en) 2013-11-06
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
EP2397132A3 (en) 2012-07-11
CN1988898B (zh) 2012-12-26
RU2010138410A (ru) 2012-03-27
PL1765322T3 (pl) 2014-04-30
US9169204B2 (en) 2015-10-27
CN1988898A (zh) 2007-06-27
US20080221208A1 (en) 2008-09-11
US20110288170A1 (en) 2011-11-24
ES2644984T3 (es) 2017-12-01
EP2397133A3 (en) 2012-07-11
NO20070330L (no) 2007-03-15
BRPI0511396B1 (pt) 2021-07-27
RU2007101735A (ru) 2008-07-27
ES2443194T3 (es) 2014-02-18
SI2397133T1 (sl) 2017-12-29
US20130072559A1 (en) 2013-03-21
PT2397133T (pt) 2017-10-23
MXPA06014750A (es) 2007-03-21
RS53178B (en) 2014-06-30
SI1765322T1 (sl) 2014-03-31
US10117845B2 (en) 2018-11-06
EP2397133B1 (en) 2017-07-26
US20170014368A1 (en) 2017-01-19
JP5166026B2 (ja) 2013-03-21
EP1765322A4 (en) 2008-09-17
NZ587006A (en) 2011-12-22
US7951841B2 (en) 2011-05-31
KR20130079669A (ko) 2013-07-10
HK1098696A1 (en) 2007-07-27
US9403765B2 (en) 2016-08-02
US9388130B2 (en) 2016-07-12
IL180078A (en) 2014-01-30
MX359668B (es) 2018-10-05
US20190167626A1 (en) 2019-06-06
JP2012229234A (ja) 2012-11-22
RU2554003C2 (ru) 2015-06-20
LT2397133T (lt) 2018-01-10
ES2752924T3 (es) 2020-04-06
US20130072560A1 (en) 2013-03-21
US20130079403A1 (en) 2013-03-28
ES2644981T3 (es) 2017-12-01
EP2397132A2 (en) 2011-12-21
KR101323122B1 (ko) 2013-10-30
RU2408578C2 (ru) 2011-01-10
CA2931917A1 (en) 2006-01-05
US9174936B2 (en) 2015-11-03
EP2397131A3 (en) 2012-10-31
HUE036596T2 (hu) 2018-07-30
JP5596749B2 (ja) 2014-09-24
IL180078A0 (en) 2007-05-15
CY1114873T1 (el) 2016-12-14
CN102976937A (zh) 2013-03-20
CA2571049A1 (en) 2006-01-05
AU2005257997A1 (en) 2006-01-05
EP2397131A2 (en) 2011-12-21
NZ552080A (en) 2011-03-31
PT1765322E (pt) 2014-02-05
HRP20140116T1 (hr) 2014-03-28
WO2006002097A3 (en) 2006-05-04
EP2397130A2 (en) 2011-12-21
EP2397133A2 (en) 2011-12-21
PL2397133T3 (pl) 2018-01-31
WO2006002097A2 (en) 2006-01-05
AU2005257997B2 (en) 2012-04-05
IL222347A (en) 2017-08-31
NO339969B1 (no) 2017-02-20
EP2397131B1 (en) 2019-09-11
KR20140140616A (ko) 2014-12-09
CY1119480T1 (el) 2018-03-07
ZA200700368B (en) 2008-10-29
KR20070026817A (ko) 2007-03-08
JP2008503496A (ja) 2008-02-07
IL230242A (en) 2015-10-29
EP1765322A2 (en) 2007-03-28
CA2571049C (en) 2016-08-09
EP2397130B1 (en) 2019-04-03
KR20120062946A (ko) 2012-06-14
KR101337321B1 (ko) 2013-12-06
US9162978B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
IN2012DN09335A (enrdf_load_stackoverflow)
WO2004082622A3 (en) Retinoid replacements and opsin agonists and methods for the use thereof
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
AU2016204344A1 (en) Improved methods and compositions for wound healing
MX2011001679A (es) Derivados de flavina.
UA99440C2 (uk) Похідні й аналоги n-етилхінолонів і n-етилазахінолонів
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
WO2011084803A3 (en) Coloring agents and methods of use thereof
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
MY162181A (en) Compositions and methods for modulating hemostasis
TW200738649A (en) Calcilytic compounds
TW200734306A (en) Novel compounds, their preparation and use
MX2009013982A (es) Composiciones que comprenden inhibidores de triptofano hidroxilasa.
SG148179A1 (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
IN2012DN03844A (enrdf_load_stackoverflow)
SG144941A1 (en) Naphthylene derivatives as cytochrome p450 inhibitors
TW200716130A (en) Purified form of tanaproget
SG149831A1 (en) Benzimidazole derivatives
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
SV2010003755A (es) Nuevos derivados de (piperazinilo con enlaces puente)-1-alcanona y su utilizacion como inhibidores de p75
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.